Auten Quoted in Law360 Article on Reused PTAB Positions
Taft Pharmaceutical & Life Sciences Chair Stephen Auten is quoted in the Feb. 8 Law360 article "USPTO's Take on Reused PTAB Positions May Upend Strategy." The article focuses on the USPTO's amicus brief in support of the position that a successful IPR defense should be barred at trial.
Auten states “The impact would be particularly strong for generic-drug makers, who must prevail in a district court patent case in order to get approval for their abbreviated new drug applications.”
In This Article
You May Also Like
Gray Selected for the FDCC Ladder Down Cleveland Class of 2023 Metzger and Shuster Presented on Intellectual Property to Engineering Group